ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  [Prevalence of mutations of resistance to HIV-I reverse transcriptase inhibitors among HIV-infected patients in the Southern Federal District].
 PMID: 17385442       2007       Klinicheskaia laboratornaia diagnostika
Abstract: The group of patients receiving antiviral treatment was found to have different drug resistance mutations in the HIV-1 pol gene: K70R, M184V, K219Q, T215Y/F, L74V, etc.


  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
 PMID: 17417971       2007       Retrovirology
Introduction: While the K65R mutation reduces replication fitness of HIV-1 in vitro relative to wild-type virus, it is unclear to which extent this can be extrapolated to virus replication fitness in vivo, especially when K65R is accompanied by other mutations in RT; some mutations may be compensatory (to improve replicative capacity), while the combination of K65R with certain other drug-selected mutations may be deleterious for viral replicative capacity (e.g., L74V, certain thymidine-analogue mutations), or may restore viral susceptibility to other compounds of the drug regimen.


  Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
 PMID: 17457088       2007       AIDS (London, England)
Abstract: Reverse transcriptase resistance mutations emerging on therapy differed between the groups: zidovudinelamivudine (M41L, D67N, K70R, M184V, L210W, T215Y); zidovudineabacavir (M41L, D67N, K70R, L210W, T215F/Y, K219Q); lamivudineabacavir (K65R, L74V, Y115F, M184V).


  Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
 PMID: 17496561       2007       Journal of acquired immune deficiency syndromes (1999)
Abstract: The Delta70 mutation increased resistance to lamivudine and emtricitabine alone and in combination with various resistance mutations and augmented resistance to ABC and didanosine when present together with L74V.
Abstract: The Delta70, L74V, and Q151M mutations were introduced into Hxb2 RT by site-directed mutagenesis and expressed in HIV-1 recombinants.
Abstract: We identified a deletion at codon 70 (Delta70) of HIV-1 reverse transcriptase (RT) occurring together with L74V and Q151M mutations in a sample from a tenofovir (TFV)- and abacavir (ABC)-treated patient with extensive prior antiretroviral treatment.


  HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
 PMID: 17500586       2007       PLoS computational biology
Abstract: Different patterns of covariation were frequently observed for different mutations at the same position including the RT mutations T69D versus T69N, L74V versus L74I, V75I versus V75M, T215F versus T215Y, and K219Q/E versus K219N/R, and the protease mutations M46I versus M46L, I54V versus I54M/L, and N88D versus N88S.
Method:


  Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRTI-associated mutations by apricitabine triphosphate.
 PMID: 17542154       2007       Antiviral chemistry & chemotherapy
Abstract: Other mutations such as M184V, L74V and K103N had no effect on the efficiency of chain termination by apricitabine-TP.


  Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.
 PMID: 17600392       2007       Drugs
Abstract: Didanosine may select for resistance mutations that may render the drug inactive against the virus; L74V and K65R remain as the main didanosine-related mutations.


  Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
 PMID: 17667333       2007       Journal of acquired immune deficiency syndromes (1999)
Abstract: Among baseline samples from 154 treatment-experienced patients, 8 had K65R and 44 had L74V/I by population sequencing.
Abstract: BACKGROUND: Prior abacavir (ABC) or didanosine (ddI) therapy can result in the L74V/I or K65R mutation in HIV-1 reverse transcriptase.
Abstract: CONCLUSIONS: Prior therapy with ABC or ddI can result in a population genotype that shows K65R or L74V/I but does not reveal low-level K65R present in some patients.


  Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
 PMID: 17686836       2007       Journal of virology
Abstract: Here, we characterize 10 additional mutations (L74V, K101Q, I135M/T, V179I, H221Y, K223E/Q, and L228H/R) in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase which are involved in the regulation of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Abstract: In particular, L74V and H221Y, positively correlated with Y181C, were associated with an increase in Y181C-mediated resistance to nevirapine, while  PMID: 17705165       2007       Journal of medical virology
Abstract: In treated patients, two patterns of resistance associated mutations (RAMs) were observed: (1) K65R (9.8%), L74V (7.4%), M184V (7.4%), Q151M (5%), and thymidine analogue mutations (TAMs) (9.3%) including T215Y (5.5%), in patients who underwent ddI + d4T + NVP.



Browser Board

 Co-occurred Entities




   Filtrator